BETA BIONICS INC (BBNX) Stock Fundamental Analysis

NASDAQ:BBNX • US08659B1026

13.97 USD
+0.03 (+0.22%)
At close: Feb 17, 2026
14.1 USD
+0.13 (+0.93%)
After Hours: 2/17/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, BBNX scores 3 out of 10 in our fundamental rating. BBNX was compared to 185 industry peers in the Health Care Equipment & Supplies industry. While BBNX has a great health rating, there are worries on its profitability. BBNX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year BBNX has reported negative net income.
  • BBNX had a negative operating cash flow in the past year.
BBNX Yearly Net Income VS EBIT VS OCF VS FCFBBNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • BBNX's Return On Assets of -23.59% is in line compared to the rest of the industry. BBNX outperforms 49.19% of its industry peers.
  • BBNX has a Return On Equity (-26.41%) which is in line with its industry peers.
Industry RankSector Rank
ROA -23.59%
ROE -26.41%
ROIC N/A
ROA(3y)-86.31%
ROA(5y)N/A
ROE(3y)-215.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BBNX Yearly ROA, ROE, ROICBBNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • The Gross Margin of BBNX (54.51%) is comparable to the rest of the industry.
  • The Profit Margin and Operating Margin are not available for BBNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BBNX Yearly Profit, Operating, Gross MarginsBBNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • BBNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • BBNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BBNX Yearly Shares OutstandingBBNX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
BBNX Yearly Total Debt VS Total AssetsBBNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 50M 100M

2.2 Solvency

  • BBNX has an Altman-Z score of 9.42. This indicates that BBNX is financially healthy and has little risk of bankruptcy at the moment.
  • BBNX has a Altman-Z score of 9.42. This is amongst the best in the industry. BBNX outperforms 89.19% of its industry peers.
  • There is no outstanding debt for BBNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.42
ROIC/WACCN/A
WACC9.98%
BBNX Yearly LT Debt VS Equity VS FCFBBNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

  • A Current Ratio of 10.64 indicates that BBNX has no problem at all paying its short term obligations.
  • BBNX's Current ratio of 10.64 is amongst the best of the industry. BBNX outperforms 93.51% of its industry peers.
  • A Quick Ratio of 9.83 indicates that BBNX has no problem at all paying its short term obligations.
  • BBNX has a better Quick ratio (9.83) than 92.97% of its industry peers.
Industry RankSector Rank
Current Ratio 10.64
Quick Ratio 9.83
BBNX Yearly Current Assets VS Current LiabilitesBBNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%57.14%

3.2 Future

  • BBNX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.16% yearly.
  • BBNX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.68% yearly.
EPS Next Y6.99%
EPS Next 2Y3.36%
EPS Next 3Y12.29%
EPS Next 5Y4.16%
Revenue Next Year34.8%
Revenue Next 2Y34.02%
Revenue Next 3Y37.05%
Revenue Next 5Y31.68%

3.3 Evolution

BBNX Yearly Revenue VS EstimatesBBNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
BBNX Yearly EPS VS EstimatesBBNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • BBNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BBNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BBNX Price Earnings VS Forward Price EarningsBBNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BBNX Per share dataBBNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • BBNX's earnings are expected to grow with 12.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.36%
EPS Next 3Y12.29%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BBNX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BETA BIONICS INC

NASDAQ:BBNX (2/17/2026, 8:00:02 PM)

After market: 14.1 +0.13 (+0.93%)

13.97

+0.03 (+0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-17
Earnings (Next)05-04
Inst Owners109.87%
Inst Owner Change2.77%
Ins Owners0.62%
Ins Owner Change-0.17%
Market Cap614.96M
Revenue(TTM)N/A
Net Income(TTM)-77.84M
Analysts82.35
Price Target29.95 (114.39%)
Short Float %12.61%
Short Ratio4.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.14%
Min EPS beat(2)14.89%
Max EPS beat(2)25.39%
EPS beat(4)2
Avg EPS beat(4)-130.42%
Min EPS beat(4)-470.41%
Max EPS beat(4)25.39%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)13.6%
Min Revenue beat(2)11.46%
Max Revenue beat(2)15.74%
Revenue beat(4)3
Avg Revenue beat(4)7.72%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)15.74%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.66%
PT rev (3m)15.6%
EPS NQ rev (1m)-0.69%
EPS NQ rev (3m)-0.44%
EPS NY rev (1m)2.06%
EPS NY rev (3m)2.57%
Revenue NQ rev (1m)1.43%
Revenue NQ rev (3m)3.91%
Revenue NY rev (1m)0.43%
Revenue NY rev (3m)1.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.94
P/FCF N/A
P/OCF N/A
P/B 2.09
P/tB 2.09
EV/EBITDA N/A
EPS(TTM)-1.95
EYN/A
EPS(NY)-1.81
Fwd EYN/A
FCF(TTM)-1.38
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS2.01
BVpS6.7
TBVpS6.7
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -23.59%
ROE -26.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.51%
FCFM N/A
ROA(3y)-86.31%
ROA(5y)N/A
ROE(3y)-215.12%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 915.51%
Cap/Sales 4.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.64
Quick Ratio 9.83
Altman-Z 9.42
F-Score6
WACC9.98%
ROIC/WACCN/A
Cap/Depr(3y)128.38%
Cap/Depr(5y)N/A
Cap/Sales(3y)146.62%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.97%
EPS Next Y6.99%
EPS Next 2Y3.36%
EPS Next 3Y12.29%
EPS Next 5Y4.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%57.14%
Revenue Next Year34.8%
Revenue Next 2Y34.02%
Revenue Next 3Y37.05%
Revenue Next 5Y31.68%
EBIT growth 1Y-26.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-31.87%
EBIT Next 3Y-10.38%
EBIT Next 5Y4.9%
FCF growth 1Y-57.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.78%
OCF growth 3YN/A
OCF growth 5YN/A

BETA BIONICS INC / BBNX FAQ

What is the fundamental rating for BBNX stock?

ChartMill assigns a fundamental rating of 4 / 10 to BBNX.


What is the valuation status of BETA BIONICS INC (BBNX) stock?

ChartMill assigns a valuation rating of 0 / 10 to BETA BIONICS INC (BBNX). This can be considered as Overvalued.


What is the profitability of BBNX stock?

BETA BIONICS INC (BBNX) has a profitability rating of 1 / 10.


What is the expected EPS growth for BETA BIONICS INC (BBNX) stock?

The Earnings per Share (EPS) of BETA BIONICS INC (BBNX) is expected to grow by 6.99% in the next year.